ref,first_author,journal,year,Cells,HLAs,Assay,Sequencing,num_uniquepep,num_pep,data,HLA,HLA_assignment,comments,Data_origin,Search_engine,Search_parameters,False_Discovery_rate,Post_translational_Modifications,1,Milner,MCP,2013,MCF,A*0201; B18; B44; Cw05,immunoaffinity,,,1776,yes,HLA not assigned,,,,MaxQuant in Andromeda; Mascot; Sequest in PD,"6ppm, 0.5Da",5% FDR,"Met oxidation, n-acetylation",2,Scull,Mol. Immuno.,2012,Jesthom; A2.221,A*0201; B*2705; Cw01/ A*0201,secreted HLA; immunoaffinity,,,1978,yes,HLA not assigned; A2 only?,,,,Paragon in Protein Pilot,,2% FDR,no cys alkylation,3,Hassan,MCP,2013,B-LCL HHC; JY,"A*0201, B*0702,B*4402, Cw*0501, and Cw*0702 / A*0201, B*0702, and Cw*0702",immunoaffinity,,,"15,736",yes,HLA ,,PTMs,,Mascot,"2PPM , 0.5DA",,"Met oxidation,  phosphorylation on serine, thre- onine, and tyrosine was allowed, and cysteinylation of cysteine",4,Gebreselassie,Human Immunol.,2006,U937,"A*0301 and A*3101, B*1801 and B*5101, Cw*0102 and Cw*0702",acid elution and immunoprecipitation,,,85,yes,HLA,,MALDI,,GPS system,,,,5,Weinzierl,Eur. J. Immunol.,2008,LCL721.45 and LCL721.174 ,A*0201 and B*5101,immunoprecitpitation ,,,49,yes,HLA,,TAP-dependent vs. TAP-independent,,Mascot,"0.2Da, 0.2Da",manual annotation 1%FDR,,6,Vogel ,MTNA,2013,HEK293; D407; HER911,"A*02/02, B*07/07, C*07/07, and DRB1*15/15, DQB1*06/06 ; A*68:02/68:02, B*15:03/15:03 (B72),C*12 DRB1*01:02/01:02, DQB1*05/05; A*02/24:03, B*37/51, HLA-C*06/15, and DRB1*10:01/13:01, DQB1*05/06",immunoprecipitation,,,54,yes,HLA,, rapamycin treated,,"Mascot, manual annotation",,,,7,Nijveen,Immunogenetics,2011,B-LCL JY,A*0201,immunoaffinity,,,9,yes, HLA not assigned,,HSVPdb,,Mascot,"2ppm, 0.8Da",,,8,Milner,MCP,2006,UCI-107,A*0201,immunoaffinity,,,36,yes,HLA,,,,"Sequest, Pepminer",,,,9,Hickman,JI,2004,B-LCL 721.221 ,B*1801,soluble HLA,,,200,yes,HLA,,,,"Mascot, Bio-Multiview",,,,10,Granados,Blood,2012,B-LCL from patients,"HLA-A*0101/*0205, HLA-B*1501/*5001, HLA-C*0602/ *0701, and DRB1*0101/*1104 HLA-A*0301/ 2902, HLA-B*0801/*4403, HLA-C*0701/*1601, and DRB1*0301/*0701",acid elution,,,"2,273",yes,HLA not assigned,,,,Mascot,"0.02Da, 0.5Da",,"oxidation (Met) and deamidation (Asn, Gln) ",11,Granados,Nat. comm.,2014,cells from patients,"A*03:01,*29:02; B*08:01,*44:03; C*07:01,*16:01; DRB1*03:01,*07:01",acid elution,,,6480,yes,HLA not assigned,,,,,,,,12,Juncker,Plos ONE,2013, ,,,,,"2,062",yes,HLA not assigned,,SYFPEITHY data,,,,,,13,Garcia-Medel,MCP,2012,C1R,A*6801,immunoaffinity,,,816,yes,HLA,,also MALDI,,,,,,14,Escobar,JI,2008,"K562, B-LCL WT100BIS; JO528239;  KOSE;  TISI ","B*3501, B*3502, B*3503, B*3504, B*3506, B*3508",immunoaffinity,,,927,yes,HLA,,,,,,,,15,Bourdetsky,PNAS,2014,B-LCL-JY; U937; RPMI8226,,immunoaffinity,,,"1,650",yes,HLA not assigned,,,,,,,,16,Lorente,Plos ONE,2013,T2; RMA-S,B*2705,immunoprecipitation,,,331,yes,HLA,,,,,,,,17,Hillen,Eur. J. Immunol.,2008,"M18  and B-LCL BM15 , Awells, WIL-JON , EMJ, LCL026, LCL721.45 , patient cell lines RCC026 and RCC068","B*4901; B*4402; B*4101; B*4001;B*4101; A*02, -B*51; B*4901; B*4101; B*4501",immunoprecipitation,,,699,yes,HLA,,,,"Mascot, manual annotation","0.2Da, 0.2Da",manual annotation 1%FDR,,18,Marcilla,MCP,2014,C1R,B*40:02 (also B*3503 and C*0401,immunoaffinity,,,"2,246",yes,HLA not assigned,,Phosphopeptides,,,,,,19,Buschbaum,Immunogenetics,2003,UCI-107; MDA-231 ,Cw4,soluble HLA,,,54,yes - partial,HLA,,partial data,dead link,,,,,20,Barnea,Eur. J. Immunol.,2002,"PC3, UCI-107,UCI-101, MDA-231 and MCF-7 ",A2; B7,soluble HLA,,,35,yes - partial,HLA,,partial data,dead link,,,,,21,Marcilla,MCP,2006,C1R,B*2705,immunoaffinity,,,50,yes,HLA,,,,,,,,22,Johnson,Vaccine,2009,B-LCL,"A*0201, B*1501, and C*03 ",immunoaffinity,,,"4,950",yes,HLA not assigned,,Vaccinia infection,,,,,,23,Antwi,Mol. Immuno.,2009,Panc-1; MCF-7,"A02/11, B38/38, Cw12/12 and HLA-A02/02, B18/44 and Cw05/05",acid elution,,,229,yes,HLA,,,,,,,,24,Ben Dror,Arth. Rheum.,2010,SW-1353; C-20/A4 ; HeLa-expressing B27/ Q10 cells and HEK293T,B27,soluble HLA,,,"1,186",yes,HLA not assigned,,,,,,,,25,Lopez de Castro,Tissue Antigen,2004,,B27,,,,376,yes,HLA,,,,,,,,26,Stodulkova,Immuno. Letters,2008,primary PBMCs,"A3/23, B2705/44, Cw2/4 ",immunoaffinity,,,92,yes,HLA not assigned,,,,,,,,27,Herberts,JI,2006,,?,,,,297,yes,HLA,,,,,,,,28,Merino,JBC,2005,C1R,"B*1402, B*1403",immunoaffinity,,,34,yes,HLA,,MALDI also,,,,,,29,Wahl,Human Immunol.,2010,HeLa,A*0201,"soluble HLA, immunoaffinity, acid elution",,,72,yes,HLA,,flu infection,,,,,,30,Adamopoulou,Nat. comm.,2013,,,,,,792,yes,HLA,,,,,,,,31,Costantino,Plos ONE,2012,,,,,,616,yes,HLA not assigned,,,,,,,,32,Harris,Blood,1996,,,,,,21,yes,HLA,,,,,,,,33,Cronin,HVI,2013,,,,,,336,yes,HLA not assigned,,Entinostat treatment,,,,,,34,Eichmann,Tissue Antigen,2014,,,,,,"3,095",yes,HLA,,,,,,,,35,Schittenhelm,Tissue Antigen,2014,,,,,,830,yes,HLA,,,,,,,,36,Bergseng,Immunogenetics,2014,"cell lines: CD114, 9087 STEINLIN, 9088 PF04015, 9047 PLH, 9050 MOU, 9051 PITOUT, 9037 SWEIG, 9064 AMALA, 9089 BOB","DRB1*03:01, DRB3*01:01, DQA1*05:01, DQB1*02:01, DPB1*01:01/04:01; DRB1*03:01, DRB3*01:01, DQA1*05:01, DQB1*02:01, DPA1*01, DPB1*03:01/04:01; DRB1*03:01, DRB3*01:01, DQA1*05:01, DQB1*02:01,DPA1*01, 02:01, DPB1*01:01/04:01; DRB1*0701, DRB4*01:01, DQA1*02:01, DQB1*02:02, DPA1*01:03, DPB1*15:01; DRB1*0701, DRB4*01:01, DQA1*02:01, DQB1*02:02, DPB1*01:03, DPB1*02:01; DRB1*0701, DRB4*01:01, DQA1*02:01, DQB1*02:02, DPA1*01:03, DPB1*04:01; DRB1*11:01, DRB3*02:02, DQA1*05:05, DQB1*03:01, DPA1*01:03, DPB1*04:02/04:01; DRB1*14:02, DRB3*01:01, DQA1*05:01/05:03, DQB1*03:01, DPA1*01:03, DPB1*04:02/94:01; DRB1*1104, DRB3*02:02, DQA1*05:05, DQB1*03:01, DPA1*01 DPB1*04:02",immunoprecipitation,,,"12,712",yes,HLA not assigned,,,,,,,,37,Badrinath,Haematologica,2011,,B*4403; B*4428,,,,356,yes  ,HLA assigned,,,,,,,,38,Chornoguz,MCP,2012,MCF10,DR7 DR4,immunoaffinity,,,428,yes  ,HLA assigned -partial,,,,,,,,39,Meiring,MCP,2006,B-LCL; DC,A0201; B7,,,,17,yes  ,HLA assigned,,,,,,,,40,Diaz,Immunogenetics,2005,B-LCL 45.1,HLA-DP2,immunoaffinity,,,41,yes  ,HLA-assigned,,,,,,,,41,Hassan,JBC,2014,B-LCL-HHC; B-LCL-JYpp65,"A*02:01, B*0702, B*4402, Cw*0501; HLA-A*02:01, B*0702 and Cw*0702",immunoaffinity,,,12,yes  ,HLA-assigned,,"""non-canonical length""",,,,,,42,Hombrink,JI,2013,,A0201; B*0702,immunoaffinity,,,40,yes - partial,HLA not assigned,,,,,,,,43,Zhang,Tissue antigens,2013,B-LCL C1R,B*1301,immunoaffinity,,,57,yes,HLA assigned,,,,,,,,44,Bade-Doding,Haematologica,2011,HEK-293 transfected with HLA-B*41,"B*4101; B*4102:, B*4103; B*4104; B*4105; B*4106","immunoprecitpitation, soluble HLA",,,235,yes,HLA assigned,,,,,,,,45,Hinrichs,Haematologica,2010,HEK-293 transfected with HLA-B*30,B*3001; B*3014L,"immunoprecitpitation, soluble HLA",,,62,yes - partial,HLA assigned,,,,,,,,46,Mommen,PNAS,2014,B-LCL GR,A1; A3; B7; B27,,,,"12,198",yes,HLA assigned,,,,,,,,47,Huyton,Immunogenetics,2012,B-LCL 721.221 ,B*4409,,,,214,yes,HLA assigned,,,,,,,,48,Bade-Doding,Human Immunol.,2011,B-LCL transduced with B*4402 or B*4427,B*4402; B*4427,"immunoprecipitation, soluble HLA",,,402,yes,HLA assigned,,,,,,,,49,Bassani-Sternberg,MCP,2015,"fibroblast, B-LCL-JY; SupB15WT, HCC1143, HCC1937 and HB95; SupB15RT",HLA-A*02:01; HLA-B*07:02; HLA-Cw*07:02; HLA-A*03; HLA-A*11; HLA-B*51; HLA-B*52; HLA-Cw*12:04; HLA-Cw*14:02; HLA-A*31:01; HLA-B*35:08; HLA-B*37:01; HLA-Cw*04:01; HLA-Cw*07:01HLA-Cw*06:02; HLA-A*23:01; HLA-A*24:02; HLA-B*07:02; HLA-B*40:01; HLA-Cw*03:04; HLA-Cw*07:02; HLA-A*01:01; HLA-A*02:01; HLA-B*45:01; HLA-B*18:01; HLA-Cw*05:01;HLA-Cw*07:01 ; HLA-A*03:01; HLA-A*23:01; HLA-B*08:01; HLA-B*15:18; HLA-Cw*07:02; HLA-Cw*07:04,immunoaffinity,,,"22,598",yes,HLA not assigned,,,,,,,,50,Van-Lummel,JBC,2012,HEK293 transfected with HLA-DQ2 or DQ8,"DQA1*05:01/DQB1*02:01 (HLA-DQ2cis), DQA1*03:01/DQB1*03:02 (HLA-DQ8cis), DQA1*03:01/DQB1*02:01 (HLADQ2trans),or DQA1*05:01/DQB1*03:02 (HLA-DQ8trans)",immunoaffinity,,,450,yes,supertype assigned,,,,,,,,51,Seward,MCP,2011,synovial fluid,HLA-DR*0402/1104; 0101/0401; 0101/0801; 1001/1101,immunoaffinity,,,349,yes,HLA assigned -partial,,,,,,,,52,Fissolo,MCP,2009,brain,,immunoaffinity,,,308,yes,HLA assigned,,,,,,,,53,Alvarez,Arth. Rheum.,2008,B-LCL Ben DR10,"HLA_A*0101, A*2301, B*3701, B*5101, Cw*01BH, and Cw*06BF. HLA-DR10 (DRA*0101, DRB1*1001)",immunoaffinity,,,238,yes,HLA assigned,,,,,,,,54,Sesma,JI,2005,B-LCL 721.220,HLA-B*27,immunoaffinity,,,46,yes - partial,HLA assigned,,,,,,,,55,Purcell,JI,2001,B-LCL 721.220,HLA-B*2705,immunoaffinity,,,18,yes - partial,HLA assigned,,,,,,,,56,Sesma,JBC,2002,B-LCL 721.220,HLA-B*2704; B*2706,immunoaffinity,,,39,YES- partial?,HLA assigned,,,,,,,,57,Lamas,Arth. Rheum.,1999,C1R transfected with B*2705,HLA-B*2705,acid elution,,,51,yes,HLA assigned,,,,,,,,58,Infantes,JBC,2013,C1R transfected with B*2705,HLA-B*2705,immunoaffinity,,,6,yes - partial,HLA assigned,,,,,,,,59,Dengjel,PNAS,2005,B-LCL Awells,HLA-DRB1*0401 ; HLA-DRB4*0101,immunoaffinity,,,402,yes,HLA assigned,,,,,,,,60,Clements,Human Immunol.,2007,,,,,,15,yes,HLA assigned,,,,,,,,61,Bade-Doeding,Immunogenetics,2005,HEK-293 transfected with HLA-A*6603,HLA-A*6603,immunoaffinity,,,6,yes,HLA assigned,,,,,,,,62,Bade-Doeding,Immunogenetics,2004,B-LCL 721.221 transfected with HLA-A*6602,HLA-A*6602,immunoaffinity,,,31,yes,HLA assigned,,,,,,,,63,Bade-Doding,Tissue Antigens,2011,HEK-293 transfected with sHLA-A*74,HLA-A*7404; 7406; 7407,"immunoprecipitation, soluble HLA",,,47,yes,HLA assigned,,,,,,,,64,Elamin,Tissue antigens,2010,HEK-293 transfected with HLA-A*0302,HLA-A*0302,"immunoprecipitation, soluble HLA",,,17,yes,HLA assigned,,,,,,,,65,Ramos,JBC,2002,"C1R transfected with B*2705, B*2709",HLA-B*2705; B*2709,immunoaffinity,,,64,yes - partial?,HLA assigned,,,,,,,,66,Fiorillo,Eur. J. Immunol.,1997,B-LCL Ci ; B-LCL GM06826a,B*2705; B*2709,immunoaffinity,,,24,yes,HLA assigned,,,,,,,,67,Boisgerault,J. Clin. Invest.,1996,C1R transfected with B*2705; B*2703,B*2705; B*2703,immunoaffinity,,,9,yes,HLA assigned,,,,,,,,68,Luckey,JI,2001,721,"Cw04, B51, B8",immunoaffinity,,,80,yes,HLA assigned -partial,,,,,,,,69,Krausa,Tissue antigens,2000,C1R transfected with A*30,HLA-A*3001; 3002; 3003; 3004,immunoaffinity,Edman,,15,yes,HLA assigned,,,,,,,,70,Trujillo,JBC,2014,"B-LCLs (Jeshtom, COX, BOLETH, SCHU, STEINLIN); 721 and C1R transfectants",,immunoaffinity,Mass spec,,773,yes,HLA assigned,,,,,,,,71,MacDonald,J Exp Med,2003,B-LCL Hmy2.C1R transfected with B*44,B*4402; B*4403,immunoaffinity,Mass spec & Edman,,14,yes,HLA assigned,,,,,,,,72,Zarling,PNAS,2006,Cancer cells and B-LCL (JY),A2,immunoaffinity,Mass spec,,36,yes,HLA assigned,,phosphopeptides,,,,,,73,Lampen,Mol. Immuno.,2013,K562 transfected with HLA-E*0103,HLA-E*0103,immunoaffinity,Mass spec,,552,yes,HLA assigned,,,,,,,,74,Wahlstrom,J. Clin. Invest.,2007,BAL of HLA-DRB1*0301,HLA-DRB1*0301,immunoaffinity,Mass spec,,78,yes,HLA assigned,,patients with sarcoidosis,,,,,,75,Seeger,Immunogenetics,1999,C1R transfected with A*6601,HLA-A*6601,immunoaffinity,Edman and Mass spec,,15,yes,HLA assigned,,,,,,,,76,Gomez,Eur. J. Immunol.,2006,C1R transfected with B*27,HLA-B*27,immunoaffinity,Mass spec,,72,yes - partial,HLA-assigned,,,,,,,,77,Kruger,Cancer Immunol Immunotherapy,2005,,,,,,52,yes,HLA assigned,,,,,,,,78,Dengjel,Cancer R R,2006,,,,,,463,yes,HLA not assigned,,,,,,,,79,VanDamme,MCP,2014,"HCT116; A-431; THP-1; K-562, Jurkat and HeLa",,immunoaffinity,Mass spec  ,,"4,110",yes,HLA not assigned,,,,,,,,80,Seliger,Proteomics,2011,MZ2733RC,"A*02:01/A*01, B*07:02/B*49 and C*05:01/Cw*0702",immunoaffinity,Mass spec,,49,yes,HLA assigned,,,,,,,,81,Depontieu,PNAS,2009,"1363-mel, 2048-mel, 1558-mel, 1102-mel, 397-mel and 1087-mel; 1363-EBV, 2048EBV, 1558-EBV, 1102-EBV, 1087-EBV, MCF-7 and LoVo; HEK293 expressing HLA-DRB1*0101",HLA-BRbeta1*0101,immunoaffinity,Mass spec,,108,yes - partial,HLA assigned,,Phosphopeptides,,,,,,82,Dutoit,Brain,2012,glioblastoma,,,Mass spec,,10,yes - partial,HLA assigned,,glioblastoma,,,,,,83,Mohme,Brain,2013,glioblastoma,,,Mass spec,,265,yes,HLA assigned -partial,,,,,,,,84,Weinzierl,MCP,2006,"Renal cell carcinoma RC099, RC100 , RC110","HLA-A*02, -A*03, -B*27, and -B*57; HLA-A*02, -A*03, -B*07, and -B*18; (HLA-A*02, -A*68, -B*18, and -B*27",,Mass spec,,275,yes - partial,HLA assigned,,renal cell carcinoma,,"Mascot, manual annotation","0.2Da, 0.2Da",manual annotation 1%FDR,,85,Meyer,JPR,2009,"Renal Cell carcinoma RCC414, B-LCL-JY, MaMel-8a","HLA-A*02, -A*24, -B*07, -B*35; HLA-DRB1*04, -DRB1*13; HLA-DRB1*01 ",immunoprecipitation,Mass spec,,79,yes- partial,HLA assigned,,Phosphopeptides; renal cell carcinoma,,,,,,86,Klug,Current Pharmaceutical Design,2009,,HLA-B*3801,immunoprecipitation,Mass spec,,58,yes,HLA assigned,,,,,,,,87,Shetty,J Proteomics,2011,lung cancer cells CRL-5865 and CRL-5944,,immunoprecipitation,Mass spec,,68,yes,HLA not assigned,,lung cancer,,,,,,88,Stickel,CII,2009,"RCC377, RCC399, RCC343 ","A*01, A*03, B*07, Cw*07; A*01, A*02, B*08, B*50, Cw*06, Cw*07",immunoprecipitation,Mass spec,,149,yes,HLA assigned,,renal cell carcinoma,,,,,,89,Alvarez,PCA,2007,HCC SK-Hep-1 cell line,"HLA-A*0201,2402; B*3502, 4403.",immunoprecipitation,Mass spec,,116,yes,HLA assigned,,,,,,,,90,Neumann,CII,2013,lung cancer,,immunoprecipitation,Mass spec,,159,yes,HLA assigned,,,,,,,,91,Neidert,J Neuro Onco,2013,tumor glioblastoma,,immunoprecipitation,Mass spec,,160,yes,HLA assigned,,,,,,,,92,Pietra,CDD,2009,,HLA-E,,,,12,yes,HLA assigned,,also viral peptides,,,,,,93,Espinosa,J P,2013,thymus,,,,,287,yes  ,HLA not assigned,,,,,,,,94,Collado,EJI,2013,thymus and bone marrow,,,,,456,yes,HLA assigned,,,,,,,,95,Berlin,Leukemia,2014,PBMC and bone marrow,,immunoprecipitation,Mass spec,,605,yes - partial,HLA assigned -partial,,,,,,,,96,Hombrink,CCR,2015,,,,,,"2,034",yes - partial,HLA assigned,,,,,,,,97,Hassan,JBC,2015,B-LCL HHC; JYpp65,,immunoaffinity,Mass spec,,"1,645",yes - partial,HLA assigned,,,,,,,,98,Jarmalavicius,JBC,2012,"melanoma ChaMel41, ChaMel84, ChaMel100, ChaMel105","HLA-A1, -A11, -B35, -B57, Cw4, and Cw6; HLA- A11,-A24, -B8, -B51, and Cw7;HLA-A11, -A32, -B35, -B51, Cw2, and Cw4;-A24, -B8, -B51, and Cw7; HLA-A2, -A11, -B35, -B60 (B4001), Cw3, and Cw4.",immunoprecipitation,Mass spec,,482,yes - partial,HLA assigned,,,,,,,,99,Kowalewski,PNAS,2015,,,,Mass spec,,523,yes - partial,HLA assigned,,,,,,,,100,Sidney,JI,2002,"cell lines: 145b, KT3, LG2, MAT, OLL, PF, PITOUT, PREISS, STEINLIN, YAR",,immunoprecipitation,Mass spec,,29,yes - partial,HLA assigned,,,,,,,,101,Prilliman,JI,1999,,,,Edman,,44,yes - partial,,,,,,,,,102,Khalil-Dahrer,EJI,1998,,,,,,14,,,,,,,,,,103,Schirle,EJI,2000,,,,,,50,,,,,,,,,,104,Alvarez,JBC,2001,,,,,,36,,,,,,,,,,105,Barber,Tissue antigens,2001,,,,,,5,yes -partial,,,,,,,,,106,Lemmel,Nature Biotech,2004,B-LCL C1R-A2 or solid tumors,A2,,,,7,yes - partial,HLA assigned,,,,,,,,107,Lippolis,JI,2002,,,,,,154,yes,HLA assigned,,,,,,,,108,Goodenough,PNAS,2014,HeLa S3,,immunoprecipitation,Mass spec,,19,yes - partial,HLA not assigned,,,,,,,,109,Ostrov,PNAS,2012,721.221 with B*57:01,B*57:01,elution,Mass spec,,934,,,,,,,,,,110,Norcross,AIDS,2012,721.221 with B*57:01,B*57:01,soluble HLA,,,29,,,,,,,,,,111,Chen,Arth. Rheum.,2014,Hela-B27; C1R.B27,B27,,,,54,,,,,,,,,,112,Yang,JACI,2007,,B*1502,soluble HLA,Mass spec,,152,yes,HLA assigned,,,,,,,,113,Pritchard,Pigment Cell Melanoma Research,2015,,"A*02:01,A*01:01, B*0702, B*4402, B*27:05; A*24:02; A*03:01",,Mass spec,,59,yes,HLA assigned,,,,,,,,114,Schittenhelm,Arth. Rheum.,2015,,B*27 family,,,,"15,600",yes,HLA assigned,,,,,,,,115,Sanz-Bravo,Arth. Rheum.,2015,,B*2705,,,,470,yes,HLA assigned,,,,,,,,116,Alvarez-Navarro,MCP,2015,,A*2902,,,,"5,584",yes,HLA assigned,,,,,,,,117,Metushi,Plos ONE,2015,721.221 with B*57:01,B*57:01,immunoprecipitation,Mass spec,,355,yes,HLA assigned,,acyclovir treated and untreated,,,,,,118,Giam,Tissue antigens,2015,,,,,,,,,,,,,,,,119,Badrinath,Immunogenetics,2012,,B*44:08,,,,49,,,,,,,,,,120,Alvarez,J Autoimm.,2015,,"HLA-DRB*0101, 0301, 0401",,,,145,,,,thymus,,,,,,121,Braud,Eur. J. Immunol.,1997,,,,,,,,,,,,,,,,122,Garcia-Medel,MCP,2014,,B27,,,,2230,,,,,,,,,,123,Dumrese,Immunogenetics,1998,,A26,,,,11,,,,,,,,,,124,Seeger,Immunogenetics,1999,,B*15:10,,,,14,,,,,,,,,,125,Caron,eLife,2015,,,,,,,,,,,,,,,,126,Schellens,Plos ONE,2015,,,,,,,,,,,,,,,,127,Kraemer,Stem Cells International,2015,,,,,,,,,,,,,,,,128,Walz,Blood,2015,,,,,,,,,,,,,,,,129,Celik,Immunogenetics,2015,,HLA-E*01:03,,,,,,,,,,,,,,130,Herman,eLife,2015,,,,,,,,,,,,,,,,131,Laumont,Nat. comm.,2016,,,,,,,,,,,,"Xcalibur, Mascot","5ppm, 0.02Da",,"cysteinylation,phosphorylation (Ser, Thr and Tyr), oxidation (Met) and deamidation (Asn, Gln).",132,Clement,JBC,2016,,,,,,,,,,,,,,,,133,Manandhar,Immunogenetics,2016,,,soluble HLA,,,,,,,,,Mascot,,,,134,Spencer,Proteomics Clin. Appl.,2015,,,,,,,,,,,,Sequest,,3.6% FDR,,135,Gleimer,JI,2011,,,,,,,,,,,,,,,,136,Guasp,Arth. Rheum.,2016,,,,,,,,,,,,"MaxQuant, Amdromeda","20ppm, 20ppm",1% FDR,oxidation of methionine,137,McMurtrey,eLife,2016,,,,,,,,,,,,PEAKS,,1% FDR,,138,Thommen,JI,2012,,,,,,,,,,,,,,,,139,Lauterbach,Human Immunol.,2015,,HLA-E,,,,,,,,,,,,,,140,Trolle,JI,2016,,,soluble HLA,,,,,,,,,PEAKS,"50ppm, 0.05Da",1% FDR,"N-terminal acetylation, deamidation of Asn and Gln, oxidation of Met,His, Trp, sodium adducts of Asp, Glu, C terminus, and the pyroglutamatederivative of glutamic acid",141,Marcilla,JPR,2016,,,,,,,,,,,,,,,,142,Ritz,Proteomics ,2016,,,,,,,,,,,,"PD-Sequest, MaxQuant","4ppm, 0.02Da",1% FDR,oxidation of methionine,143,Schittenhelm,MCP,2016,,,,,,,,,,,,Skyline,5ppm,,,144,Kowalewski,Blood Cancer Journal,2016,,,,,,,yes - partial,,,,,Mascot,,5% FDR,oxidation of methionine,145,Mommen,MCP,2016,MUTZ-3 DC,"HLA-DR10, -DR11, -DR52, DRB1*10, DRB1*11, DRB3*01","Immunoprecipitation, acid elution",Mass spec,,10,yes - partial,HLA not assigned,,,,PD,"3ppm, 0.02Da",1% FDR,"methylation and dimethylation (Arg, Lys) acetylation (Nterminus, Lys), cysteinylation (Cys), deamidation (Asn, Gln, Arg) andoxidation (Met)",146,Lorente,MCP,2016,,,,,,,,,,,,"Sequest in PD, Bioworks","0.005Da, 0.5Da",1% FDR,"cysteinilation(C), oxidation (M, P, H, F, Y, and W), methylation (C, and N-terminus), andphosphorylation (Y, S, and T).",147,Ciudad,J. Leuk. biol.,2016,,,,,,,,,,,,Sequest in PD,"10ppm, 0.6Da",1% FDR,oxidation of methionine,148,Scholz,Arth. Rheum.,2016,,,"immunoprecipitation, Maldi-TOF",,,,,,,,,MS Handler,0.25Da,,,149,Van Lummel,JI,2016,,,,,,,,,,,,Mascot,"10ppm, 0.02Da",,,150,Shraibman,MCP,2016,,,,,,,,,,,,"MaxQuant, andromeda","4.5ppm, 20ppm",5% FDR,"oxidation of methionine, Carbamidomethyl cysteine, Methionine sulfoxide and n-acetylation",151,Heyder,MCP,2016,,,,,,,,,,,,Mascot,"5ppm, 0.02 or 0.25Da",5% FDR,,152,GranadoS-Leukemia,,2016,,,,,,,,,,,,,,,,153,Nyambura,JI,2016,,,,,,,,,,,,Mascot,"50ppm, 100ppm",5% FDR,oxidation of methionine,154,Cobbold-STM,,2013,,,,,,,,,,,,manual annotation,,,,155,Zarling-JEM,,2000,,,,,,,,,,,,,,,,156,Zarling-JI,,2003,,,,,,,,,,,,,,,,157,Martin-ESteban-JBC,,2014,,,,,,,,,,,,,,,,158,Mohammed-NatImm,,2008,,,,,,,,,,,,,,,,159,Brickner-JEM-,,2001,,,,,,,,,,,,,,,,160,PeterSen-PNAS-,,2009,,,,,,,,,,,,,,,,161,Zota-JI,,2009,,,,,,,,,,,,,,,,162,Malaker,JPR,2016,,,,,,,,,,,,manual annotation,,,,163,Marino,JACS,2015,,,,,,,,,,,,,,,,164,Marino,JPR,2016,,,,,,,,,,,, Sequest in PD,"10ppm, 0.05Da",1% FDR,"Methionine oxidation, arginine mono-methylation and arginine di-methylation",165,Gloger,CII,2016,,,,,,,,,,,,MaxQuant ,"4.5ppm, 20ppm",1% FDR,oxidation of methionine,166,HawkinS-JPR,,2008,,,,,,,,,,,,Mascot or de novo,"0.5Da, 0.5Da",,phosphorylation or sulfation,167,Kourjian,JI,2016,,,,,,,,,,,,Mascot,"5ppm , 0.02Da",1% FDR,,168,Wang,JPR,2016,,,,,,,,,,,,"Mascot, OMSSA, X!Tandem","0.01Da, 0.5Da, 10ppm, 20mmu, 20ppm, 50mmu",,"Cysteinylation of cysteine,deamidation of glutamine and asparagine, pyroglutamic acid from amino-terminal glutamine andglutamic acid, and oxidation of methionine",169,Liepe,Science,2016,,,,,,,,,,,,Mascot (Sequest too -not shown),"3ppm, 0.02Da; 6ppm, 20ppm",,"Asparaginedeamidation, methionine oxidation, cysteinylation, phosphorylation (S, T, Y), or N-terminalglutamate cyclization were",170,PearSon,J. Clin. Invest.,2016,,,,,,,,,,,,"Xcalibur, Mascot","5ppm, 0.02Da",,"cysteinylation,phosphorylation (Ser, Thr and Tyr), oxidation (Met) and deamidation (Asn, Gln).",171,Bassani-Sternberg,Nat. comm.,2016,,,,,,,,,,,,"MaxQuant, Andromeda","6ppm, 20ppm",1%FDR,"N-terminal acetylation (42.010565 Da), methionine oxidation (15.994915 Da) andphosphorylation (79.9663304 Da on serine, threonine and tyrosine)",172,Alpizar,MCP,2016,"C1R transfected with B*40:02, B*39:01 and GR",B*40:02 (also B*35:03 and C*0401),IP,Mass spec,,7340,yes  ,HLA assigned -partial,,,,"Mascot, OMSSA, X!Tandem2, Myrimatch","0.01Da, 0.02Da",1%FDR,"oxidation of methionine, protein N_terminalacetylation, pyroglutamic acid formation from N_terminal glutamine or glutamic acid andphosphorylation of serine, threonine and tyrosine.",173,Martin-Esteban,J Autoimm.,2017,,,,,,,,,,,,"MaxQuant, Andromeda","20ppm, 20ppm",1%FDR,,174,Ramakrishna,International Immunity,2003,OVCAR 3; SKOV3.A2,A*02:01,,,,,,,,,,,,,,175,Pymm,Nature Structutal and Molecular Biology,2017,C1R transfected with B*57:01,B*57:01,IP,Mass spec,,11954,yes,HLA assigned,, +/- Gag,,,,,,176,Abelin,Immunity,2017,,,,,,,,,,,,Spectrum Mill,"10ppm, 20ppm",,,177,Loffler,J. Hep.,2016,,,,,,,,,,,,"PD, Mascot","5ppm, 0.5Da",5% FDR,,178,Badrinath,J I R,2014,,,,,,,,,,,,,,,,179,Peters,Cancer Immunol Immunotherapy,2017,,,,,,,yes - partial,,,,,,,,,180,Khodadoust,Nature,2017,,,,,,,,,,,,"Sequest, PEAKS","20ppm, 0.02Da",1% FDR,"oxidation of methionines and deamidation (N, Q), cysteinylation, and phosphorylation (S, T, Y)",181,Sim,Frontiers in Immunology,2017,,,,,,,,,,,,"OMSSA, manual validation",,,,182,Murphy,JPR,2017,,,,,,,,,,,,Sequest or Mascot in PD,"5ppm, 0.5Da",5% FDR,,183,Guasp,JBC,2017,,,,,,,,,,,,"MaxQuant, andromeda","20ppm, 20ppm",1% FDR,"oxidation (Met), acetyl (protein N-terminus) and Gln to Pyro-Glu",184,Yamashita,Nat. comm.,2017,,,,,,,,,,,,MaxQuant,"10ppm, 10ppm",1% FDR,"oxidation of methionine, in addition to N-terminalprotein acetylation,",185,Hilton,Cell Reports,2017,,,,,,,,,,,,PEAKS; Skyline,50ppm,1% FDR,"N-terminal acetylation, deamidation (Asn, Gln),oxidation (Met, Trp, His), pyro-glu from Gln, cysteinylation (Cys), sodium adduct (C-term, Asp,Glu) - max 2 per peptides",partial?186,Kochin-OncoImmunology-2017,Oncoimmunology,2017,,,,,,,,,,,,,,,,partial?187,Neerincx,eLife,2017,,,,,,,,,,,,Mascot,,10% FDR,"CAM cysteine as a fixed modification and acetyl N640terminus and oxidised methionine as variable modifications",188,Muixi,JI,2008,,,,,,,,,,,,"Mascot, MS-Tag",,,,189,Dulberger,Immunity,2017,,,,,,141818,,,,,,PEAKS,,,"N-terminal acetylation, deamidation (N,Q), Oxidation (M,W,H), Pyro-glu from Q, Cysteinylation (C), Sodium adduct (c-term, D,E),Phosphorylation (T,S,Y).",190,Kaur,Nat. comm.,2017,,,,,,,,,,,,Protein Pilot,,5% FDR,,191,Hoffman-MCP-2005,MCP,2005,,,,,,,,,,,,,,,,192,Klatt,Oncoimmunology,2016,,,,,,,,,,,,Mascot in PD,"5ppm, 0.5Da",5% FDR,oxidation of Met,partial193,Flad,Cancer Research,1998,,,,,,,,,,,,,,,,194,Hawkins,JPR,2008,,,,,,,,,,,,,,,,195,Malaker,C I R,2017,,,,,,,,,,,,manual interpretation,,,,196,Bassani-Sternberg,Plos Comp. Biol,2017,,,,,,,,,,,,MaxQuant,"6ppm, 20ppm",1% FDR,"N-terminal acetylation, met oxidation",197,Ritz,Proteomics,2017,,,,,,,,,,,,Sequest,,,,198,Zappacosta,PNAS,1997,,,,,,,,,,,,,,,,199,Mobbs,JBC,2017,,,,,,,,,,,,Protein Pilot,,5% FDR,,200,Synowsky,JBC,2017,,,,,,,,,,,,Mascot,"20ppm, 0.1Da",,oxidation,201,Scholz,Frontiers in Immunology,2017,,,,,,,,,,,,Mascot,"15ppm, 0.025Da",5% FDR,"N-terminal acetylation, pyroglutamic acidformation from glutamine, and methionine oxidation",202,DiMarco,JI,2017,,,,,,,,,,,,Sequest,"5ppm, 0.02Da",5% FDR,oxidation of Met,203,Martin-Esteban,Arth. Rheum.,2017,,,,,,,,,,,,"MaxQuant, andromeda","20ppm, 20ppm",1% FDR,"oxidation (Met), acetyl (protein N-terminus) and Gln to Pyro-Glu",204,Strug,JPR,2008,,,,,,,,,,,,,,,,205,Escobar,JPR,2011,,,,,,,,,,,,,,,,206,Goodridge,JI,2010,,,,,,,,,,,,,,,,partial